Biotechs line up for a busy week of IPOs

As skeptics and enthusiasts banter back and forth over whether the biotech industry is seeing a bubble on Wall Street, a number of biotechs aren't waiting around for a definitive answer. In a busy week for IPOs in general, four biotechs are planning to go public this week. Seres Therapeutics leads the bunch with a $100 million offering to support its work on the microbiome. Microstent glaucoma devicemaker Glaukos, a medical device company, is also up alongside Cambridge, MA-based Catabasis and Germany's Pieris, the latest European outfit to land at Nasdaq in search of investors cash. Story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.